Insights
Recon takes an analytical look behind select developments in healthcare
Keep up with Recon Strategy Insights
Get an email each time we publish a new article
Search
- By Marc Herant
Is the lack of new (non-viral) antibiotics a market failure?
A lament about the lack of success in getting the biopharma industry to invest sustainably in the development of new antibiotics against h…
- By Tory Wolff
MSFT’s pathbreaking alliances in healthcare services are impressive and well designed to grow adoption of their Azure cloud over the medium term. But if MSFT wants to be at the forefront of change an…
- By Marc Herant
Huntington’s disease: light at the end of the tunnel?
The awful thing about Huntington’s is that in most cases, people know they are going progressively lose their mind at an early age, but there is …
- By Marc Herant
A clinical vignette: the cases of Jane and Joe
Imagine if you will two individuals both at age 50. Jane is a project manager whose recent health care has focused on managing menopausal symptoms, a kn…
- By Tory Wolff
Summary
The Capital Region of Pennsylvania is shifting in “real time” from traditionally separate plan vs. plan competition and provider vs. provider competition to integrated vertical plan/provider …
- By Marc Herant
TAVR for all?
TAVR has become the standard of care for patients who need an aortic value replacement but are at high/medium surgical risk. But what about those at low-risk? Two studies answer that qu…
- By Sophie Ranen
Amazon’s healthcare play appears to be heavily focused on platforms rather than specific applications
They would prefer startups focus on elements that are truly differentiating for consumers and let …
- By Tory Wolff
By bringing together accountable-minded physicians, urgent care and ambulatory surgery centers (ASCs) on a national scale, OptumCare could prevent a lot of avoidable hospital care and move much of wha…
- By Marc Herant
He’s dead, Jim
As previously widely advertised, the BACE-1 inhibitor verubecestat (Merck) (and in journal correspondence atabecestat, Janssen) has now failed in a population with very early signs of c…